Dual expression system for assembling phage lambda display particle (LDP) vaccine to porcine Circovirus 2 (PCV2)

Vaccine

Volumn 28, Issue 41, 2010, Pages 6789-6799

  Hayes, Sidney ^a   Gamage, Lakshman N A ^b   Hayes, Connie ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Bacteriophage lambda D fusion expression system; Lambda surface display particle (LDP) vaccine; PCV ORF2 capsid protein; Porcine Circovirus 2

Indexed keywords

CAPSID PROTEIN; HYBRID PROTEIN; LAMBDA DISPLAY PARTICLE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE LAMBDA; CELLULAR IMMUNITY; CIRCOVIRIDAE INFECTION; CIRCOVIRUS; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSION VECTOR; GENE EXPRESSION; GENE EXPRESSION SYSTEM; HETEROIMMUNE PHAGE; HUMORAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHAGE DISPLAY; PLASMID; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PURIFICATION; SWINE; VIRUS ASSEMBLY; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BACTERIOPHAGE LAMBDA; BASE SEQUENCE; CAPSID PROTEINS; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; EPITOPES; GERM-FREE LIFE; IMMUNITY, CELLULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PLASMIDS; RECOMBINANT FUSION PROTEINS; SWINE; VIRAL VACCINES;

EID: 77956458105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.047     Document Type: Article

References (65)

1. Whitman W.B., Coleman D.C., Wiebe W.J. Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 1998, 95(June (12)):6578-6583.
2. Dabrowska K., Switala-Jelen K., Opolski A., Weber-Dabrowska B., Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol 2005, 98(1):7-13.
3. Gorski A., Weber-Dabrowska B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 2005, 62(March (5)):511-519.
4. Merril C.R., Scholl D., Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2(June (6)):489-497.
5. Payne R.J., Jansen V.A. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 2003, 42(4):315-325.
6. Bruttin A., Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005, 49(July (7)):2874-2878.
7. Aronow R., Danon D., Shahar A., Aronson M. Electron microscopy of in vitro endocytosis of T2 phage by cells from rabbit peritoneal exudate. J Exp Med 1964, 120(November (1)):943-954.
8. Clark J.R., March J.B. Bacterial viruses as human vaccines?. Expert Rev Vaccines 2004, 3(August (4)):463-476.
9. Geier M.R., Trigg M.E., Merril C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973 Nov 23, 246(5430):221-223.
10. Reynaud A., Cloastre L., Bernard J., Laveran H., Ackermann H.W., Licois D., et al. Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Vet Microbiol 1992, 30(February (2-3)):203-212.
11. Barrow P., Lovell M., Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 1998, 5(May (3)):294-298.
12. Mullen L.M., Nair S.P., Ward J.M., Rycroft A.N., Henderson B. Phage display in the study of infectious diseases. Trends Microbiol 2006, 14(March (3)):141-147.
13. Dunn I.S. Assembly of functional bacteriophage lambda virions incorporating C-terminal peptide or protein fusions with the major tail protein. J Mol Biol 1995, 248(May (3)):497-506.
14. Garufi G., Minenkova O., Lo Passo C., Pernice I., Felici F. Display libraries on bacteriophage lambda capsid. Biotechnol Annu Rev 2005, 11:153-190.
15. Maruyama I.N., Maruyama H.I., Brenner S. Lambda foo: a lambda phage vector for the expression of foreign proteins. Proc Natl Acad Sci USA 1994, 91(August (17)):8273-8277.
16. Mikawa Y.G., Maruyama I.N., Brenner S. Surface display of proteins on bacteriophage lambda heads. J Mol Biol 1996, 262(September (1)):21-30.
17. Santini C., Brennan D., Mennuni C., Hoess R.H., Nicosia A., Cortese R., et al. Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. J Mol Biol 1998, 282(September (1)):125-135.
18. Sternberg N., Hoess R.H. Display of peptides and proteins on the surface of bacteriophage lambda. Proc Natl Acad Sci USA 1995, 92(February (5)):1609-1613.
19. Danner S., Belasco J.G. T7 phage display: a novel genetic selection system for cloning RNA-binding proteins from cDNA libraries. Proc Natl Acad Sci USA 2001, 98(November (23)):12954-12959.
20. Efimov V.P., Nepluev I.V., Mesyanzhinov V.V. Bacteriophage T4 as a surface display vector. Virus Genes 1995, 10(2):173-177.
21. Jiang J., Abu-Shilbayeh L., Rao V.B. Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect Immun 1997, 65(November (11)):4770-4777.
22. Ren Z.J., Lewis G.K., Wingfield P.T., Locke E.G., Steven A.C., Black L.W. Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4. Protein Sci 1996, 5(September (9)):1833-1843.
23. Ren Z.J., Tian C.J., Zhu Q.S., Zhao M.Y., Xin A.G., Nie W.X., et al. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 2008, 26(March (11)):1471-1481.
24. Ansuini H., Cicchini C., Nicosia A., Tripodi M., Cortese R., Luzzago A. Biotin-tagged cDNA expression libraries displayed on lambda phage: a new tool for the selection of natural protein ligands. Nucleic Acids Res 2002, 30(August (15)):e78.
25. Beghetto E., Pucci A., Minenkova O., Spadoni A., Bruno L., Buffolano W., et al. Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries. Int J Parasitol 2001, 31(December (14)):1659-1668.
26. Kuwabara I., Maruyama H., Kamisue S., Shima M., Yoshioka A., Maruyama I.N. Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods 1999, 224(April (1-2)):89-99.
27. Lin J.T., Lis J.T. Glycogen synthase phosphatase interacts with heat shock factor to activate CUP1 gene transcription in Saccharomyces cerevisiae. Mol Cell Biol 1999, 19(May (5)):3237-3245.
28. Minenkova O., Pucci A., Pavoni E., De Tomassi A., Fortugno P., Gargano N., et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 2003, 106(September (4)):534-544.
29. Niwa M., Maruyama H., Fujimoto T., Dohi K., Maruyama I.N. Affinity selection of cDNA libraries by lambda phage surface display. Gene 2000, 256(October (1-2)):229-236.
30. Santi E., Capone S., Mennuni C., Lahm A., Tramontano A., Luzzago A., et al. Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics. J Mol Biol 2000, 296(February (2)):497-508.
31. Zucconi A., Dente L., Santonico E., Castagnoli L., Cesareni G. Selection of ligands by panning of domain libraries displayed on phage lambda reveals new potential partners of synaptojanin 1. J Mol Biol 2001, 307(April (5)):1329-1339.
32. Benhar I. Biotechnological applications of phage and cell display. Biotechnol Adv 2001, 19(February (1)):1-33.
33. Edgar R., McKinstry M., Hwang J., Oppenheim A.B., Fekete R.A., Giulian G., et al. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes. Proc Natl Acad Sci USA 2006, 103(March (13)):4841-4845.
34. Yim P.B., Clarke M.L., McKinstry M., De Paoli Lacerda S.H., Pease L.F., Dobrovolskaia M.A., et al. Quantitative characterization of quantum dot-labeled lambda phage for Escherichia coli detection. Biotechnol Bioeng 2009, 104(December (6)):1059-1067.
35. Georgopoulos C., Tilly K., Casjens S. Lambdoid phage head assembly. Lambda II. Cold Spring Harbor 1983, 279-304. Cold Spring Harbor Laboratory, New York. R.W. Hendrix, J.W. Roberts, F.S. Stahl, R.A. Weisberg (Eds.).
36. Katsura I. Structure and function of the major tail protein of bacteriophage lambda. Mutants having small major tail protein molecules in their virion. J Mol Biol 1981, 146(March (4)):493-512.
37. Gupta A., Onda M., Pastan I., Adhya S., Chaudhary V.K. High-density functional display of proteins on bacteriophage lambda. J Mol Biol 2003, 334(November (2)):241-254.
38. Hayes S. Phage lambda display constructs. United States Patent application serial no. 61/051,712 (2008); International Application No. PCT/CA209/000603. International Publication No. WO2009/135295 A1.
39. Bastien N., Trudel M., Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology 1997, 234(July (1)):118-122.
40. D'Apice L., Sartorius R., Caivano A., Mascolo D., Del Pozzo G., Di Mase D.S., et al. Comparative analysis of new innovative vaccine formulations based on the use of procaryotic display systems. Vaccine 2007, 25(March (11)):1993-2000.
41. Delmastro P., Meola A., Monaci P., Cortese R., Galfre G. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine 1997, 15(August (11)):1276-1285.
42. Morales J., Martinez J.J., Manoutcharian K., Hernandez M., Fleury A., Gevorkian G., et al. Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine 2008, 26(June (23)):2899-2905.
43. Gamage L.N., Ellis J., Hayes S. Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes. Vaccine 2009, 27(November (47)):6595-6604.
44. March J.B., Clark J.R., Jepson C.D. Genetic immunisation against hepatitis B using whole bacteriophage lambda particles. Vaccine 2004, 22(April (13-14)):1666-1671.
45. Clark J.R., March J.B. Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol Med Microbiol 2004, 40(January (1)):21-26.
46. Clark J.R., March J.B. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 2006, 24(May (5)):212-218.
47. Gaubin M., Fanutti C., Mishal Z., Durrbach A., De Berardinis P., Sartorius R., et al. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 2003, 22(January (1)):11-18.
48. Jepson C.D., March J.B. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 2004, 22(June (19)):2413-2419.
49. Hayes S., Bull H.J., Tulloch J. The Rex phenotype of altruistic cell death following infection of a lambda lysogen by T4rII mutants is suppressed by plasmids expressing OOP RNA. Gene 1997, 189(April (1)):35-42.
50. Hayes S., Slavcev R.A. Polarity within pM and pE promoted phage lambda cI-rexA-rexB transcription and its suppression. Can J Microbiol 2005, 51(January (1)):37-49.
51. Hayes S., Szybalski W. Control of short leftward transcripts from the immunity and ori regions in induced coliphage lambda. Mol Gen Genet 1973, 126(November (4)):275-290.
52. Zeghouf M., Li J., Butland G., Borkowska A., Canadien V., Richards D., et al. Sequential Peptide Affinity (SPA) system for the identification of mammalian and bacterial protein complexes. J Proteome Res 2004, 3(May-June (3)):463-468.
53. Slavcev R.A., Hayes S. Blocking the T4 lysis inhibition phenotype. Gene 2003, 321 (December):163-171.
54. Szybalski W., Szybalski E.H. Equilibrium density gradient centrifugation. Procedures in Nucleic Acid Research 1971, 311-354. Harper & Row, New York:. G.L. Davies, D.R. Davies (Eds.).
55. Kaiser A.D. On the internal structure of bacteriophage lambda. J Gen Physiol 1966, (July):171-178.
56. Daniels D.L., Schroeder J.L., Szybalski W., Sanger F., Coulson A.R., Hong G.F., Hill D.F., Petersen G.B., Blattner F.R. Complete annotated lambda sequence. Lambda II 1983, 519-676. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. R.W. Hendrix, J.W. Roberts, F.S. Stahl, R.A. Weisberg (Eds.).
57. Mahe D., Blanchard P., Truong C., Arnauld C., Le Cann P., Cariolet R., et al. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J Gen Virol 2000, 81(July (Pt 7)):1815-1824.
58. Meehan B.M., McNeilly F., Todd D., Kennedy S., Jewhurst V.A., Ellis J.A., et al. Characterization of novel circovirus DNAs associated with wasting syndromes in pigs. J Gen Virol 1998, 79(September (Pt 9)):2171-2179.
59. Imber R., Tsugita A., Wurtz M., Hohn T. Outer surface protein of bacteriophage lambda. J Mol Biol 1980, 139(May (3)):277-295.
60. Dokland T., Murialdo H. Structural transitions during maturation of bacteriophage lambda capsids. J Mol Biol 1993, 233(October (4)):682-694.
61. Yang F., Forrer P., Dauter Z., Conway J.F., Cheng N., Cerritelli M.E., et al. Novel fold and capsid-binding properties of the lambda-phage display platform protein gpD. Nat Struct Biol 2000 Mar, 7(March (3)):230-237.
62. Sternberg N., Weisberg R. Packaging of coliphage lambda DNA. II. The role of the gene D protein. J Mol Biol 1977, 117(December (3)):733-759.
63. Forrer P., Jaussi R. High-level expression of soluble heterologous proteins in the cytoplasm of Escherichia coli by fusion to the bacteriophage lambda head protein D. Gene 1998, 224(December (1-2)):45-52.
64. Wurtz M., Kistler J., Hohn T. Surface structure of in vitro assembled bacteriophage lambda polyheads. J Mol Biol 1976, 101(February (1)):39-56.
65. Zanghi C.N., Lankes H.A., Bradel-Tretheway B., Wegman J., Dewhurst S. A simple method for displaying recalcitrant proteins on the surface of bacteriophage lambda. Nucleic Acids Res 2005, 33(18):e160.